{"id":62014,"date":"2026-03-31T20:00:35","date_gmt":"2026-03-31T12:00:35","guid":{"rendered":"https:\/\/flcube.com\/?p=62014"},"modified":"2026-03-31T20:00:38","modified_gmt":"2026-03-31T12:00:38","slug":"luye-pharma-reports-31-1-profit-surge-driven-by-new-product-growth-and-oncology-cns-segment-strength","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62014","title":{"rendered":"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\/CNS Segment Strength"},"content":{"rendered":"\n<p><strong>Luye Pharma Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2186:HKG\">HKG: 2186<\/a>) has announced its <strong>2025 financial results<\/strong>, reporting <strong>RMB 6.308 billion<\/strong> (USD 912 million) in revenue with a <strong>31.1% year-over-year increase in net profit<\/strong> to <strong>RMB 619 million<\/strong> (USD 89.6 million). The strong performance was driven by <strong>56.8% growth in new product sales<\/strong> and robust expansion in oncology and central nervous system (CNS) therapeutic segments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Result<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>RMB 6.308B (USD 912M)<\/td><td>+4.1%<\/td><\/tr><tr><td><strong>Net Profit (Attributable)<\/strong><\/td><td>RMB 619M (USD 89.6M)<\/td><td>+31.1%<\/td><\/tr><tr><td><strong>New Product Sales Growth<\/strong><\/td><td>Not disclosed (revenue contribution)<\/td><td>+56.8%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-segment-performance\">Therapeutic Segment Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>2025 Revenue<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Oncology<\/strong><\/td><td>RMB 2.297B (USD 332M)<\/td><td>+10.2%<\/td><\/tr><tr><td><strong>Central Nervous System (CNS)<\/strong><\/td><td>RMB 2.028B (USD 293M)<\/td><td>+25.7%<\/td><\/tr><tr><td><strong>Metabolic<\/strong><\/td><td>RMB 3.488B (USD 504M)<\/td><td>-10.3%<\/td><\/tr><tr><td><strong>Cardiovascular<\/strong><\/td><td>RMB 1.152B (USD 166M)<\/td><td>-30.6%<\/td><\/tr><tr><td><strong>Other Areas<\/strong><\/td><td>RMB 482M (USD 69.7M)<\/td><td>+53.2%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>Note: Segment revenues sum to RMB 9.449B due to overlapping product classifications or reporting methodology<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-growth-drivers-analysis\">Strategic Growth Drivers Analysis<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-new-product-engine\">New Product Engine<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>56.8% YOY growth<\/strong> in new product sales represents the primary driver of margin expansion<\/li>\n\n\n\n<li>Successful commercial launches across multiple therapeutic areas<\/li>\n\n\n\n<li>Enhanced pricing power and market positioning for innovative products<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-oncology-leadership\">Oncology Leadership<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RMB 2.297B revenue<\/strong> (+10.2%) solidifies position in China&#8217;s rapidly growing oncology market<\/li>\n\n\n\n<li>Portfolio likely includes biosimilars and innovative targeted therapies<\/li>\n\n\n\n<li>Benefits from increasing cancer incidence and improved diagnosis rates in China<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cns-resurgence\">CNS Resurgence<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>25.7% growth<\/strong> to RMB 2.028B reflects strong demand for neurological and psychiatric treatments<\/li>\n\n\n\n<li>Potential drivers include aging population, mental health awareness, and premium product launches<\/li>\n\n\n\n<li>Higher-margin segment contributing significantly to profit expansion<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-challenging-segments-assessment\">Challenging Segments Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Performance Issue<\/th><th>Strategic Implications<\/th><\/tr><\/thead><tbody><tr><td><strong>Cardiovascular<\/strong><\/td><td>-30.6% decline to RMB 1.152B<\/td><td>Generic competition, patent expirations, or portfolio rationalization<\/td><\/tr><tr><td><strong>Metabolic<\/strong><\/td><td>-10.3% decline to RMB 3.488B<\/td><td>Market saturation, pricing pressure, or competitive dynamics in diabetes\/obesity space<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The cardiovascular and metabolic segment declines highlight the ongoing challenges in mature therapeutic areas facing intense generic competition and pricing pressure in China&#8217;s evolving healthcare landscape.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-outlook\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Profit Margin Expansion:<\/strong> 31.1% profit growth significantly outpacing 4.1% revenue growth indicates successful product mix optimization<\/li>\n\n\n\n<li><strong>Innovation Focus:<\/strong> New product growth engine validates R&amp;D investment strategy and commercial execution capabilities<\/li>\n\n\n\n<li><strong>Therapeutic Diversification:<\/strong> Strong performance in high-growth areas (oncology, CNS) offsets challenges in mature segments<\/li>\n\n\n\n<li><strong>China Market Position:<\/strong> Well-positioned to benefit from government policies favoring innovative domestic pharmaceutical companies<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Success in domestic market provides foundation for international expansion of proprietary products<\/li>\n<\/ul>\n\n\n\n<p>The financial results demonstrate Luye Pharma&#8217;s successful transition toward a more innovation-driven business model, with new products and high-growth therapeutic areas driving sustainable profitability.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Luye Pharma&#8217;s financial performance and strategic direction. Actual results may vary based on market conditions, regulatory developments, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033100246_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026033100246_c.\"><\/object><a id=\"wp-block-file--media-65e4542e-1ce2-4484-9f19-e2dd43766bea\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033100246_c.pdf\">2026033100246_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033100246_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-65e4542e-1ce2-4484-9f19-e2dd43766bea\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Luye Pharma Group (HKG: 2186) has announced its 2025 financial results, reporting RMB 6.308 billion&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62016,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,1023,219],"class_list":["post-62014","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-2186","tag-luye-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\/CNS Segment Strength - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Luye Pharma Group (HKG: 2186) has announced its 2025 financial results, reporting RMB 6.308 billion (USD 912 million) in revenue with a 31.1% year-over-year increase in net profit to RMB 619 million (USD 89.6 million). The strong performance was driven by 56.8% growth in new product sales and robust expansion in oncology and central nervous system (CNS) therapeutic segments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62014\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\/CNS Segment Strength\" \/>\n<meta property=\"og:description\" content=\"Luye Pharma Group (HKG: 2186) has announced its 2025 financial results, reporting RMB 6.308 billion (USD 912 million) in revenue with a 31.1% year-over-year increase in net profit to RMB 619 million (USD 89.6 million). The strong performance was driven by 56.8% growth in new product sales and robust expansion in oncology and central nervous system (CNS) therapeutic segments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62014\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T12:00:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T12:00:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62014#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62014\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\\\/CNS Segment Strength\",\"datePublished\":\"2026-03-31T12:00:35+00:00\",\"dateModified\":\"2026-03-31T12:00:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62014\"},\"wordCount\":453,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62014#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3102-1.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 2186\",\"Luye Pharma\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62014#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62014\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62014\",\"name\":\"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\\\/CNS Segment Strength - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62014#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62014#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3102-1.webp\",\"datePublished\":\"2026-03-31T12:00:35+00:00\",\"dateModified\":\"2026-03-31T12:00:38+00:00\",\"description\":\"Luye Pharma Group (HKG: 2186) has announced its 2025 financial results, reporting RMB 6.308 billion (USD 912 million) in revenue with a 31.1% year-over-year increase in net profit to RMB 619 million (USD 89.6 million). The strong performance was driven by 56.8% growth in new product sales and robust expansion in oncology and central nervous system (CNS) therapeutic segments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62014#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62014\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62014#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3102-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3102-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\\\/CNS Segment Strength\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62014#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\\\/CNS Segment Strength\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\/CNS Segment Strength - Insight, China&#039;s Pharmaceutical Industry","description":"Luye Pharma Group (HKG: 2186) has announced its 2025 financial results, reporting RMB 6.308 billion (USD 912 million) in revenue with a 31.1% year-over-year increase in net profit to RMB 619 million (USD 89.6 million). The strong performance was driven by 56.8% growth in new product sales and robust expansion in oncology and central nervous system (CNS) therapeutic segments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62014","og_locale":"en_US","og_type":"article","og_title":"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\/CNS Segment Strength","og_description":"Luye Pharma Group (HKG: 2186) has announced its 2025 financial results, reporting RMB 6.308 billion (USD 912 million) in revenue with a 31.1% year-over-year increase in net profit to RMB 619 million (USD 89.6 million). The strong performance was driven by 56.8% growth in new product sales and robust expansion in oncology and central nervous system (CNS) therapeutic segments.","og_url":"https:\/\/flcube.com\/?p=62014","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-31T12:00:35+00:00","article_modified_time":"2026-03-31T12:00:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62014#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62014"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\/CNS Segment Strength","datePublished":"2026-03-31T12:00:35+00:00","dateModified":"2026-03-31T12:00:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62014"},"wordCount":453,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62014#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102-1.webp","keywords":["Finanical Reports","HKG: 2186","Luye Pharma"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62014#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62014","url":"https:\/\/flcube.com\/?p=62014","name":"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\/CNS Segment Strength - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62014#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62014#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102-1.webp","datePublished":"2026-03-31T12:00:35+00:00","dateModified":"2026-03-31T12:00:38+00:00","description":"Luye Pharma Group (HKG: 2186) has announced its 2025 financial results, reporting RMB 6.308 billion (USD 912 million) in revenue with a 31.1% year-over-year increase in net profit to RMB 619 million (USD 89.6 million). The strong performance was driven by 56.8% growth in new product sales and robust expansion in oncology and central nervous system (CNS) therapeutic segments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62014#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62014"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62014#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102-1.webp","width":1080,"height":608,"caption":"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\/CNS Segment Strength"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62014#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Luye Pharma Reports 31.1% Profit Surge Driven by New Product Growth and Oncology\/CNS Segment Strength"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3102-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62014"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62014\/revisions"}],"predecessor-version":[{"id":62017,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62014\/revisions\/62017"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62016"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}